Gefitinib Tablets
Gefitinib tablets are categorized as kinase inhibitor, which exhibits anti-cancer activity by undergoing mechanism like protein kinase inhibition, the main ingredient which is used as Gefitinib Iressa. Gefitinib which is chemically known as anilinoquinazoline which contains anti-neoplastic effects..
Available brands in Gefitinib are:
INDICATION
Gefitinib is considered as first line therapy in non-small cell lung carcinoma in metastatic stage, tumor cell containing epidermal growth factor receptors like exon 19 deletion or exon 21 substitution mutations which is identified by FDA approved test.
The mean bioavailability of Gefitinib is 60% The peak plasma concentration time of Gefitinib Iressa is reaches within 3 to 7 hours after drug intake Gefitinib is distributed throughout the body and causes steady state volume of distribution in 1400L The human plasma protein bound of Gefitinib Iressa is occurs as 90%. The metabolism of Gefitinib is occurs through hepatically, by using CYP3A4. Three sections of biotransformation occurs in metabolism of Gefitinib includes as; 1. Metabolism of N-propoxymorpholino group 2. Methoxy substituent on quinazoline demethylation occur 3. Halogenated phenyl group undergoes oxidative defluorination The major active metabolite of Gefitinib is O desmethyl Gefitinib Iressa which is formed by CYP2D6 metabolism. Gefitinib is cleared away with the help of liver, with half life elimination occurring within 48 hours. The steady state plasma concentration is accomplished within 10 days after daily single dose. The elimination of Gefitinib is occurs through feces with the range of 86% and renal elimination also occurred with less than 4%.
OVER DOSAGE
There is no distinct therapy for over dosage of Gefitinib, if over dosage occurs provide supportive care and monitor the patients frequently for the signs and symptoms of over dosage of Gefitinib Iressa.For More Information
Call Us
+91-97890 77748
Mail to
info@blueberrypharma.com
No comments:
Post a Comment